

VITAMIN D<sub>3</sub> PRODUCTION BY CULTURED HUMAN KERATINOCYTES AND FIBROBLASTS

Michael K. Nemanic, JoAnne Whitney, Sara Arnaud,  
Su Herbert, Peter M. Elias\*

Dermatology Service (190), V.A. Medical Center,  
4150 Clement Street, San Francisco, CA 94121

Received July 21, 1983

**SUMMARY:** We have demonstrated that monolayers of human cultured newborn foreskin keratinocytes and fibroblasts elaborate vitamin D<sub>3</sub> following exposure to UV-B. This *in vitro* system provides a new means to study those factors (hormones, ions, vitamin D<sub>3</sub> metabolites, etc.) that regulate the production of vitamin D<sub>3</sub> by human skin cells. Vitamin D<sub>3</sub> production was enhanced greatly by using cells that were pre-treated with AY-9944, a non-toxic drug that inhibits cholesterologenesis while elevating cellular levels of 7-dehydrocholesterol, the sterol precursor of vitamin D<sub>3</sub>. The pre-D<sub>3</sub> formed within viable, irradiated cells is transformed to D<sub>3</sub> within a matter of hours at 37°C, and keratinocytes proved to be more proficient sources of the vitamin and its metabolites than corresponding skin fibroblasts.

Although the skin's ability to generate 7-dehydrocholesterol (7-DHC) (1-5) and vitamin D<sub>3</sub> (D<sub>3</sub>) (6-8) has been appreciated for decades, only recently have details of the chemical events that follow ultraviolet UV-irradiation of skin been elucidated (9-12). Although the photoproduction of D<sub>3</sub> is considered to be a passive process, governed largely by the availability of UV light and 7-DHC, recent reports have presented evidence that cutaneous D<sub>3</sub> production may be influenced by circulating D<sub>3</sub> metabolites (13-17). However, studies on the regulation of D<sub>3</sub> production in the skin have been impeded by the lack of a homogeneous *in vitro* system suitable for testing variables that might orchestrate the synthesis and release of D<sub>3</sub> from the skin.

\* To whom correspondence should be addressed..

**Abbreviations:**

7-dehydrocholesterol (7-DHC); vitamin D<sub>3</sub> (D<sub>3</sub>); pre-vitamin D<sub>3</sub> (pre-D<sub>3</sub>); ultraviolet (UV); fetal calf serum (FCS); phosphate-buffered saline (PBS); high pressure liquid chromatography (HPLC); and N=(nitrogen).

In order to assess the capacity of different skin cell types to generate  $D_3$ , we compared the production of  $D_3$  and its sterol precursors in irradiated first- or second-passage cultured keratinocytes and fibroblasts derived from newborn human foreskins (18). When we found that the small intracellular pool of 7-DHC in the cultured cells precluded photoproduction of significant amounts of  $D_3$  following irradiation, we added AY-9944, a pharmacologic inhibitor of the  $\Delta^7$ -reduction of 7-DHC to cholesterol (19-21), which resulted in the accumulation of large quantities of 7-DHC and  $D_3$ . Using this system we report here : (1) that both cultured keratinocytes and fibroblasts are capable of generating  $^3H$ - $D_3$  via 7-DHC from  $^3H$ -acetate after UV-B irradiation; and (2) that keratinocytes generate more  $D_3$  per cell than skin-derived fibroblasts.

#### METHODS

**Materials:**  $^3H$  acetic acid (sodium salt) (1.8 Ci/mmol),  $^3H$   $D_3$  (18 Ci/mmol),  $^3H$  cholesterol (80 Ci/mmol) were obtained from New England Nuclear Corp. Unlabeled sterol esters, lanosterol,  $D_3$ , cholesterol, desmosterol, 7-DHC, and lathosterol were obtained from Sigma Chemical Co. Zymosterol was a gift from Dr. L.W. Parks, Oregon State University, Corvallis, OR. Pre- $D_3$ , lumisterol, and tachysterol were prepared from irradiated 7-DHC (10). Tissue culture media and supplies were obtained from the cell culture facility at the University of California, San Francisco. Fetal calf serum (FCS) was purchased from Sterile Systems, Inc. AY-9944 was a gift from Dr. D. Dvornik, Ayerst Pharmaceuticals. HPLC grade n-hexane, 2-propanol, and ethyl acetate were purchased from Burdick and Jackson Chemicals. Samples were stored in 1.5 ml amber specimen vials (teflon-sealed) from Pierce Chemical Co.

**Cells:** Newborn human foreskin keratinocytes were co-cultivated with mitomycin-C-treated 3T3 feeder cells. Foreskin fibroblasts were grown in medium (DME) supplemented with 10% newborn calf serum.

**Cell Treatments:** Confluent first or second passage keratinocytes (99% fibroblast-free) or dermal fibroblasts were incubated with  $^3H$ -acetate (250  $\mu$ Ci) overnight (37°C, 5%  $CO_2$  in air) in cell culture medium containing 5-20% FCS, either untreated or delipidized (23), or in medium without serum and factors except antibiotics and amphotericin B. Following incubations, the cells were rinsed with ice-cold PBS, and designated dishes, kept at 4°C, were irradiated for 15-20 min. from above with a 100W mercury arc lamp equipped with a 295 nm barrier filter (WG-295, Schott Optical Co., Duryea, PA), or with a narrow pass 290  $\pm$  5 nm filter (Oriel Corp., Stamford, CT) (total dose UV-B in both cases  $\approx$  0.5 J/cm<sup>2</sup>). Following this treatment, irradiated and control cells were scraped, pelleted and the pellets were extracted at 4°C overnight in methanol:diethyl ether (2:7).

**Preparation for HPLC:** The organic phase of the cell extract was removed, dried under nitrogen gas and resuspended in 0.5 ml of 0.5% isopropanol in n-hexane. An aliquot of each sample was fractionated by HPLC on a Partisil-5 column (Whatman) equilibrated with 0.5% isopropanol-n-hexane (2 ml/min., 500 p.s.i.). Whereas 6% ethyl acetate in n-hexane was used to separate desmosterol from 7-DHC and lathosterol,  $D_3$  and cholesterol co-migrated in this solvent system.  $D_3$  could then be separated

from cholesterol and tachysterol in 0.2% isopropanol-n-hexane (4 ml/min, 1500 psi).

### RESULTS

Keratinocytes and fibroblasts, labeled overnight with  $^3\text{H}$ -acetate, produced radiolabeled compounds from irradiated 7-DHC that separated on HPLC into fractions that co-migrated with authentic sterol esters, lanosterol, zymosterol, pre- $\text{D}_3$ , lumisterol, and tachysterol (Fig 1a). The UV spectra for authentic pre- $\text{D}_3$ ,  $\text{D}_3$ , tachysterol, and 7-DHC standards




Figure 1: Characterization of the sterols produced by cultured human keratinocytes. (A) Normal phase HPLC separation of lipids extracted from  $^3\text{H}$ -acetate-labeled keratinocytes with and without prior exposure to UV-B (290 + 7nm). Pre- $\text{D}_3$ , lumisterol, tachysterol and  $\text{D}_3$  were generated in the irradiated cultures only. (B) The pre- $\text{D}_3$  regions from (A) with and without UV, were heated to 60°C under  $\text{N}_2$  to convert pre- $\text{D}_3$  to  $\text{D}_3$  and then they were re-chromatographed on HPLC ( $\text{A}_{254}$ ) as shown.  $\text{D}_3$  appeared exclusively from the pre- $\text{D}_3$  region of the irradiated cells. (C) The UV spectra generated by the peaks isolated from (A). The  $\text{D}_3$  spectrum was taken from the  $\text{D}_3$  isolated from (B). (D) Normal phase HPLC separation of sterols from UV-irradiated 7-dehydrocholesterol (HPLC solvent system for 1a and 1d, 0.2% isopropanol-n-hexane; for 1b, 0.5% isopropanol-n-hexane).

TABLE I: DISTRIBUTION OF RADIOLABELED ACETATE INTO VITAMIN D<sub>3</sub> AND ITS PRECURSORS IN KERATINOCYTES AND FIBROBLASTS: INFLUENCE OF AY-9944 (cpm) \*

CELL TYPE	FRACTIONS/REGIONS	CONDITIONS			
		CONTROL		AY-9944	
		(+UV)	(-UV)	(+UV)	(-UV)
Fibroblasts	Pre-D <sub>3</sub>	1,770	2,340	5,295	930
	D <sub>3</sub>	0	0	735	0
	Cholesterol	42,795	52,680	0	0
	Desmosterol/7-DHC	8,595	12,240	23,190	38,685
	Zymosterol	0	0	5,940	5,415
Keratinocytes	Pre-D <sub>3</sub>	3,615	3,825	24,180	2,100
	D <sub>3</sub>	0	0	10,410	0
	Cholesterol	136,695	183,540	0	0
	7-DHC	150	150	65,940	71,820
	Zymosterol	0	0	53,595	45,765

\* The cells were grown to confluence in DME + 20% FCS + cholera toxin, EFG and hydrocortisone, then incubated with 250  $\mu$ Ci <sup>3</sup>H-acetate and AY-9944 (1  $\mu$ g/ml) for 15 hours; results comparable to these were obtained when AY-9944 was used at 0.15  $\mu$ g/ml. Some cells were irradiated with UV (>290 nm), then all were scraped, extracted and prepared for HPLC. An aliquot of each sample was injected into the HPLC.

were identical to the same HPLC-fractionated compounds generated by the cells (Fig. 1), and all of these compounds were definitively identified by mass spectrometry (24). The D<sub>3</sub> UV-spectrum, shown in Figure 1c, was produced by first heating the pre-D<sub>3</sub> fraction obtained from irradiated cells followed by rechromatography on HPLC to isolate the D<sub>3</sub> fraction.

Whereas small amounts of D<sub>3</sub> were formed by both keratinocytes and fibroblasts in irradiated, non-drug-treated cultures, addition of AY-9944 (0.15-0.3  $\mu$ g/ml), a dose two orders of magnitude below its LD<sub>50</sub>, completely blocked cholesterol production in both fibroblasts and in keratinocytes, resulting in substantial increases in the levels of both 7-DHC and zymosterol (Fig. 1a, Table I). Lower doses yielded less 7-DHC, but even doses as low as 0.003  $\mu$ g/ml produced substantial blockade (data not shown). In these experiments higher dose levels were employed in order to maximize the pool size available for photoconversion. In the doses employed here, AY-9944 did not exert toxic effects on the cells as evidenced by unaltered mitotic rates and unaltered rates of synthesis of non-polar lipids, free sterols and total lipid (Tables I & II)

TABLE II: INFLUENCE OF UV-B AND AY-9944 REMOVAL ON ACETATE INCORPORATION INTO VITAMIN D<sub>3</sub> AND OTHER STEROLS IN CULTURED KERATINOCYTES\*

TIME(Hrs)	UV-B*	PRE-D <sub>3</sub>	FRACTIONS (cpm)			ZYMOST	TOTAL COUNTS IN LIPID
			D <sub>3</sub>	CHOL	7-DHC		
(+AY) 0-24	+	17,732	7,634	0	48,356	39,303	8 x 10 <sup>6</sup>
	-	1,540	0	0	52,558	33,561	7 x 10 <sup>6</sup>
(+AY) (-AY) 0-24 24-48	+	3,916	15,114	0	175,835	110	15 x 10 <sup>6</sup>
	-	3,135	3,740	440	486,552	110	31 x 10 <sup>6</sup>
(+AY) 0-48	+	3,554	12,848	0	114,499	63,943	15 x 10 <sup>6</sup>
	-	4,785	3,091	0	345,059	99,187	32 x 10 <sup>6</sup>

\*The cells were exposed to UV at 24 hrs while in PBS. All incubations were in DME + 5% FCS + 250  $\mu$ Ci <sup>3</sup>H-acetic acid + AY-9944 (0.3  $\mu$ g/ml) at 37°C in 5% CO<sub>2</sub>/air. An aliquot (5-10%) of the total lipid extract was fractionated on HPLC.

Following UV-B treatment, 7-DHC levels decreased while pre-D<sub>3</sub> and D<sub>3</sub> peaks increased in both keratinocytes and fibroblasts (Fig. 1a, Table I). Keratinocytes produced more 7-DHC, pre-D<sub>3</sub>, D<sub>3</sub>, lumisterol, and tachysterol per cell than comparably treated fibroblasts (Table I). In the absence of UV-B both cell types produced small amounts of an unidentified compound that co-migrated on HPLC with pre-D<sub>3</sub>, but did not yield D<sub>3</sub> upon heating (Fig. 1b). In non-irradiated samples the D<sub>3</sub> region was devoid of significant radioactivity (Fig. 1a, Table I). The efficiency of photoconversion of irradiated cellular 7-DHC to pre-D<sub>3</sub> and D<sub>3</sub> was as high as 70% (Tables I and II).

After removal of AY-9944, the keratinocytes continued to produce 7-DHC without zymosterol, as their main free sterol (Table II), without resumption of cholesterol production for an additional 5 days (data not shown). The pre-D<sub>3</sub> produced in samples irradiated at 24 hours was transformed to D<sub>3</sub> following a second 24 hour incubation at 37°C (nearly all of the D<sub>3</sub> appearing in the first 4-6 hours). Although UV-B irradiation cut the rate of 7-DHC synthesis in half, keratinocytes continued to produce both 7-DHC and zymosterol during the post-irradiation period (Table II).

## DISCUSSION

These results demonstrate, for the first time, that both skin keratinocytes and fibroblasts generate vitamin D<sub>3</sub> following in vitro exposure to UV-B. The observation that keratinocytes produce more D<sub>3</sub> than fibroblasts can be explained by the fact that the former cells metabolize acetate to cholesterol, via 7-DHC, at a greater rate (Table I). Whereas previous studies of vitamin D<sub>3</sub> production in human skin have been limited to either human volunteers or short-term organ cultures, with the in vitro system described here, it will be possible to perform studies on the regulation of vitamin D<sub>3</sub> production by hormones, vitamin D metabolites, ions and other factors in homogeneous cell populations, and under precisely defined conditions. We have shown elsewhere that several factors (calcium, hydrocortisone, EGF), alone and in combination, can modulate 7-DHC levels in cultured human keratinocytes by as much as 30-fold (25), and that cultured keratinocytes generate several, as yet incompletely identified, D<sub>3</sub> metabolites from <sup>3</sup>H-25-OH-D<sub>3</sub> (26).

An important observation in these studies relates to the preferential utilization of the  $\Delta^7$  vs.  $\Delta^{24}$  pathway by human keratinocytes. In contrast to other cell types (27-31), keratinocytes in vivo (32-34) and in vitro (these studies) produce 5-8 times more 7-DHC than desmosterol, indicating that the  $\Delta^7$ -reductase may be the rate-limiting enzyme in post-lanosterol cholesterol biosynthesis in the epidermis, and pointing to the  $\Delta^7$  reductase as a potential control point of both cholesterologenesis and D<sub>3</sub> generation in the skin. The fact that the 7-DHC levels are much higher in epidermis in vivo than in vitro, further suggests that epidermal cells can adjust  $\Delta^7$ -reductase activity over a wide range. Future studies will determine whether in vivo D<sub>3</sub> (via 7-DHC levels) is regulated not only by the dose of UV-B striking the skin, but also by factors such as those that control the D<sub>3</sub>-endocrine system.

## REFERENCES

1. Windaus, A., Boch, F. (1937) Z. Physiol. Chem. 245,168-174.
2. Miller, W.L., Bauman, C.A. (1954) Proc. Soc. Exp. Biol. Med. 85,561-564.

3. Wheatley, V.R., Reinertson, R.P. (1958) *J. Invest. Dermatol.* 31,51-54.
4. Gaylor, J.L., Sault, F.M. (1964) *J. Lipid Res.* 5,422-431.
5. Yasumura, M., Okano, T., Mizuno, K., Kobayashi, T. (1977) *J. Nutr. Sci. Vitaminol.* 23,513-523.
6. Rauschkolb, E.W., Davis, H.W., Fenimore, D.C., Black, H.S., Fabre, L.F. (1969) *J. Invest. Dermatol.* 53,289-293.
7. Okano T., Yasumura M., Mizuno K., Kobayashi T. (1978) *J. Nutr. Sci. Vitaminol.* 24,47-63.
8. Esvelt, R.P., Schnoes, H.K., De Luca, H.F. (1978) *Arch. Biochem. Biophys.* 188,282-286.
9. Holick, M.F., Frommer, H.E., McNeill, S.C., Richtand, N., Henley, J.W., Potts, Jr., J.T. (1977) *Biochem. Biophys. Res. Commun.* 76,107-114.
10. Holick, M.F., Richtand, N.M., McNeill, S.C., Holick, S. A., Frommer, J.E., Henley, J.W., Potts, Jr., J.T. (1979) *Biochemistry* 18,1003-1008.
11. Holick, M.F., Uskokovic, M., Henley, J.W., MacLaughlin, J., Holick, S.A., Potts, Jr., J.T. (1980) *N. Engl. J. Med.* 303,349-354.
12. Holick, M.F., MacLaughlin, J.A., Clar, M.B., Holick, S.A., Potts, Jr., J.T., Anderson, R.R., Blank, I.H., Parrish, J.A., Elias, P.M. (1980). *Science* 210,203-205.
13. Stumpf, W.E., Sar, M., Reid, F.A., Tanaka, Y., De Luca, H.F. (1979) *Science* 206,1188-1189.
14. Feldman, D., Chen, T., Hirst, M., Colston, K., Karasek, M. Cone, C. (1980) *J. Clin. Endocr. Metab.* 51,1463-1465.
15. Simpson, R.V., De Luca, H.F. (1980) *Proc. Nat. Acad. Sci.* 77,5822-5826.
16. Laouari, D., Pavlovitch, H., Deceneux, C., Balsan, S. (1980) *FEBS Lett.* 111,285-289.
17. Esvelt, R.P., De Luca, H.F., Wichmann, J.K., Yoshizawa, S., Zuvacher, J., Sar, M., Stumpf, V.E. (1980) *Biochemistry* 19,6158-6161.
18. Nemanic, M.K., Herbert, S., Elias, P.M. (1983) *Clin. Res.* 31,468A.
19. Ahrens, R.A., Dupont, J., Thompson, M.J. (1965) *Proc. Soc. Exp. Biol. Med.* 118,436.
20. Kraml, M., Dubuc, J., Dvornik, D. (1967) *Lipids* 2,5-7.
21. Emmons, G. T., Rosenblum, E.R., Melloy, J.M., MacManus, I.R., Campbell, I.M. (1980) *Biochem. Biophys. Res. Commun.* 96,34-38.
22. Rheinwald, J.G., Green, H. (1975) *Cell* 6,331-340.
23. Havel, R., Eder, A., Bragdon, J.H. (1955) *J. Clin. Invest.* 34,1345-1353.
24. Nemanic, M.K., Elias, P.M. (1983) Manuscript in preparation.
25. Nemanic, M.K., Bikle, D., Elias, P.M. (1983) *Calcified Tiss. Intern.* In press.
26. Nemanic, M.K., Bikle, D. (1983) *Fed. Proc.* 42(3),1178a.
27. Lock, K. (1965) *Science* 150,19.
28. Goad, L.J. (1970) *Biochem. Soc. Symp.* 29,45-48.
29. Miller, W.L., Kolafer, M.E., Gaylor, J.L., Delwiche, C.V. (1967) *Sterol Biosynth.* 6,2673-2675.
30. Schroepfer, G.F. (1981) *Ann. Rev. Biochem.* 50,585-621.
31. Schroepfer, G.F. (1982) *Ann. Rev. Biochem.* 51,555-585.
32. Reinertson, R.P., Wheatley, V.R. (1962) *J. Invest. Dermatol.* 32,49-59.
33. Gray, G.M., Yardley, H.J. (1965) *J. Lipid Res.* 16,435-440.
34. Elias, P.M., Lampe, M.A., Chung, J-C, Williams, M.W. (1983) *J. Lipid Res.*, 48,565-577.